EUVIMEDEUVIMED entdecken
Crossref

Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma

Aida Nasirishargh, Monica Grova, Cyrus P Bateni, Sean J Judge, Miriam A Nuno, Ugur Nur Basmaci, Robert J Canter, Sarah B Bateni

Journal of Surgical Oncology · 2023-04 · 127 (5) · 855-861

DOI: 10.1002/jso.27199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 09.01.2023. Verfasst von Aida Nasirishargh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA. Hauptthemen laut MEDLINE: Frailty, Sarcopenia, Hypoalbuminemia, Retroperitoneal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retroperitoneal sarcomas (RPS) are rare tumors for which surgical resection is the principal treatment. There is no established model to predict perioperative risks for RPS. We evaluated the association between preoperative sarcopenia, frailty, and hypoalbuminemia with surgical and oncological outcomes.

Methods

We performed a prospective cohort analysis of 65 RPS patients who underwent surgical resection. Sarcopenia was defined as Total Psoas Area Index ≤ 1st quintile by sex. Frailty was estimated using the modified frailty index (mFI). Logistic regression models were used to assess predictors of 30‐day postoperative morbidity. The Kaplan–Meier method with log‐rank test was utilized to assess factors associated with overall (OS) and recurrence‐free survival (RFS).

Result

Sarcopenia was associated with worse OS with a median of 54 compared with 158 months ( p = 0.04), but no differences in RFS ( p > 0.05). Hypoalbuminemia was associated with worse OS with a median of 72 compared with 158 months ( p < 0.01). MFI scores were not associated with OS or RFS ( p > 0.05). Sarcopenia, mFI, and hypoalbuminemia were not associated with postoperative morbidity ( p > 0.05).

Conclusion

This study suggests that sarcopenia may be utilized as a measure of overall fitness, rather than a cancer‐specific risk, and the mFI is a poor predictive measure of outcomes in RPS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FrailtySarcopeniaHypoalbuminemiaRetroperitoneal NeoplasmsSarcomaHumansProspective StudiesRetrospective StudiesMorbidityPostoperative Complications

Stichwörter der Autor:innen

frailtyhypoalbuminemiamorbidityrecurrenceretroperitoneal sarcomasarcopeniasurvivaltotal psoas area index

Autor:innen und Institutionen

  • Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA.
  • Department of Radiology, University of California Davis Medical Center, Sacramento, California, USA.
  • Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Zitieren

APA

Nasirishargh, A., Grova, M., Bateni, C. P., Judge, S. J., Nuno, M. A., Basmaci, U. N., Canter, R. J., & Bateni, S. B. (2023). Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma. Journal of Surgical Oncology, 127(5), 855-861. https://doi.org/10.1002/jso.27199

Vancouver

Nasirishargh A, Grova M, Bateni CP, Judge SJ, Nuno MA, Basmaci UN, et al. Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma. Journal of Surgical Oncology. 2023;127(5):855-861. doi:10.1002/jso.27199

BibTeX
@article{Nasirishargh2023,
  author = {Nasirishargh, Aida and Grova, Monica and Bateni, Cyrus P and Judge, Sean J and Nuno, Miriam A and Basmaci, Ugur Nur and Canter, Robert J and Bateni, Sarah B},
  title = {Sarcopenia and frailty as predictors of surgical morbidity and oncologic outcomes in retroperitoneal sarcoma},
  journal = {Journal of Surgical Oncology},
  year = {2023},
  volume = {127},
  number = {5},
  pages = {855--861},
  doi = {10.1002/jso.27199}
}
Kostenlos starten →